The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nevro is known for its spine products and spinal cord stimulator technologies. “We believe our high-frequency technology offers clinically superior solutions that can alter the standard of care for ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...

The company made another M&A play this month with its planned acquisition of spinal cord stimulation (SCS) company Nevro. “I’m proud of our team at Globus Medical, delivering incredible ...